Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech product inventories

Executive Summary

Wholesaler inventories of Rituxan and Herceptin were on "the higher end" of the typical range at the end of Q4 and "at the lower end of the typical range by the end of March," COO Myrtle Potter says April 9. Exec stands by earlier comments that inventory buildups did not contribute to strong Q4 performance. Firm says it closely monitors inventory and has internal processes in place to eliminate speculative buying (1"The Pink Sheet" April 15, 2002, p. 27); price increases for Herceptin, Rituxan became effective in early March but did not impact first quarter results...

You may also be interested in...



Genentech Addresses Speculative Buying; No Distortions From March 1 Hikes

Genentech has effectively eliminated speculative buying by drug wholesalers in advance of price increases, Exec VP-Commercial Operations Myrtle Potter declared in an April 9 analyst call

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel